Form 4: Viemed President Moore's Routine Share Vesting

Viemed Healthcare President Michael Moore reported the vesting of restricted stock and phantom share units, alongside tax-related share dispositions.

Summary

• Michael Moore, President of Viemed Healthcare, Inc. (VMD), reported transactions on January 29, 2026, related to his executive compensation.
• Acquired 26,842 common shares through the vesting of Restricted Stock Units (RSUs), which were part of an award granted on January 29, 2024, vesting in three equal annual installments.
• Disposed of 7,342 common shares at a market closing price of $7.48 per share to satisfy tax obligations resulting from the RSU vesting.
• Acquired 8,947 common shares through the vesting of cash-settled Phantom Share Units (PSUs), also part of an award granted on January 29, 2024, vesting in three equal annual installments.
• Simultaneously disposed of 8,947 common shares at $7.48 per share for cash settlement of the vested PSUs.
• Following these transactions, Moore directly holds 189,090 common shares and indirectly holds 1,722,614 common shares through Moore Faster LLC.
• Moore also holds 26,842 unvested Restricted Stock Units and 8,947 unvested Phantom Share Units, both scheduled to vest on January 29, 2027, representing the final installment of their respective grants.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, reflecting the routine execution of an executive compensation plan rather than a discretionary action indicating a change in company prospects or performance.

Positives

• The vesting of 26,842 Restricted Stock Units and 8,947 Phantom Share Units indicates continued long-term incentive compensation for the President, aligning executive interests with shareholder value.
• Transactions are part of a pre-established vesting schedule from awards granted on January 29, 2024, demonstrating a structured and transparent executive compensation plan.

Negatives

• Disposition of 7,342 common shares for tax withholding and 8,947 common shares for cash settlement of PSUs resulted in a reduction of Michael Moore's direct common share ownership.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as the vesting of equity awards and subsequent tax-related dispositions, are common practices in executive compensation across various industries. These transactions reflect the execution of pre-established compensation plans rather than discretionary trading based on new company developments.

Related Party Transactions

• The reported transactions involve the company's President, Michael Moore, and are part of his executive compensation plan, which is a standard form of related party dealing.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine, pre-scheduled compensation events. The slight reduction in direct ownership due to tax withholding and cash settlement is an expected part of the underlying compensation structure.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The next and final installment of Restricted Stock Units and Phantom Share Units for Michael Moore is scheduled to vest on January 29, 2027.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events (vesting and tax-related dispositions) and does not provide new information that would fundamentally alter the investment thesis for Viemed Healthcare. It confirms the ongoing execution of a pre-established compensation plan. Therefore, a 'hold' recommendation is appropriate as there's no new catalyst for a change in investment stance based solely on this filing.

Keywords

Viemed Healthcare, VMD, Michael Moore, Insider Transaction, Form 4, Restricted Stock Units, Phantom Share Units, Share Vesting, Tax Withholding, Executive Compensation